"Direct partner involvement in transactions, even when the day to day drafting is being dealt with by a junior lawyer. Their main strengths are in knowing their clients so being able to deal with issues expeditiously without needing client involvement for all the minutiae of the transaction; that and an uncanny ability of overcoming items that other lawyers see as problems. They are a firm who simply get the deal done in the best interests of their clients."
Legal 500, 2020Medicinal Cannabis: the new frontier
Medicinal cannabis is, without doubt, one of the world’s fastest growing and most innovative industrial sectors. Since the turn of the century, researchers have revealed the immense potential of the drug to treat conditions from epilepsy to MS to cancer.
As a result, many countries have legalised cannabis for medicinal use, and a new sector has emerged that could be worth €115.7 billion by 2028 in Europe alone. But this is a complex new area. Memery Crystal has the expertise to help you navigate it.
Your team
Nick DavisChief Executive
Close
Contact Nick Davis
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
-
Daniel AbrahamsPartner, Co-Head of Real Estate
Nick AlfilléPartner, Head of Corporate
Michael DawesPartner, Corporate
Kieran StonePartner, Corporate
Daniel TunkelPartner, Head of Financial Regulation
-
Mark O’DonnellDirector
Melanie Talbot (née Jory)Director
Robert BlackSenior Associate
Lauren BelmonteSolicitor, Corporate
In 2018, the UK started the process of legalising medicinal cannabis. At Memery Crystal, we believe this law change represents a chance to benefit thousands of patients, support scientific innovation and fuel economic prosperity. We are committed to supporting this exciting opportunity.
The UK medicinal cannabis sector may be embryonic, but we are already at the centre of it. Memery Crystal are the leading full service UK law firm advising the medicinal cannabis sector on business set up, capital markets, mergers & acquisitions, private fundraising, licensing and commercial contracts. Our team also produced The Green Report in September 2018 to aid conversation in the emerging UK medicinal cannabis investment landscape.
Our team is well equipped to advise on the broad range of matters that this complex but highly promising new space encompasses.